Rheumatoid ArthritisPhase 2NCT00883896
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
A Phase 2 study testing ILV-094 in people with Rheumatoid Arthritis, run by Pfizer at 52 sites in 11 countries.
Trial summary
The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- ILV-094
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 195 participants
- Where
- 52 sitesin 11 countries
- Study dates
- 18 Jun 2009to 18 Feb 2011
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening
- Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following at screening: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h
- Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit.
Who cannot join
- Subjects with other rheumatic diseases
- Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer)
- Any prior use of B cell-depleting therapy
Trial locations and contacts
52 sites in 11 countries.
52 sites in 11 countries
United States13 sites
Deaconess Hospital
Cincinnati, Ohio, 45219
Arthritis Care and Diagnostic Center
Dallas, Texas, 75231
Altoona Center for Clinical Research
Duncansville, Pennsylvania, 16635
Arizona Arthritis & Rheumatology Research, PLLC
Glendale, Arizona, 85304
Diagnostic Rheumatology and Research PC
Indianapolis, Indiana, 46227
Desert Medical Advances
Palm Desert, California, 92260
Arthritis Center
Palm Harbor, Florida, 34684
Arthritis & Osteoporosis Center of South Texas
San Antonio, Texas, 78232
Clinical Research Advantage, Inc.
Sarasota, Florida, 34233
The Arthritis Specialty Centre
Sarasota, Florida, 34233
Clayton Medical Research
St Louis, Missouri, 63117
Clinical Research Center of Reading
West Reading, Pennsylvania, 19611
Clinical Research Center of Reading, LLC
Wyomissing, Pennsylvania, 19610
Japan8 sites
Inoue Hospital
Gunma, 370-0053
Matsubara Clinic
Hyōgo, 650-0001
Matsubara Mayflower Hospital
Hyōgo, 673-1462
Medical Corporation Wakoukai Kurashiki Kousai Hospital
Kurashiki, Okayama-ken, 712-8044
Gunma University Hospital
Maebashi, Gunma, 371-8511
National Hospital Organization Sagamihara National Hospital
Sagamihara, Kanagawa, 228-8522
Institute of Rheumatology, Tokyo Women's Medical University Hospital
Shinjyuku-ku, Tokyo, 162-0054
National Hospital Organization Shimoshizu National Hospital
Yotsukaidou, Chiba, 284-0003
Russia7 sites
Institute of Rheumatology of Russian academy of Medical Scie
Moscow, 115522
City Clinical Hospital # 1 n.a. Pirogov
Moscow, 119049
State Educational Institution of Additional Professional Education
Saint Petersburg, 191015
State Health care institution of Leningrad Regional Clinical Hospital
Saint Petersburg, 194291
State education institution of higher vocational education Smolensk State Medical Academy Roszdrav
Smolensk, 214019
State Healthcare Institution Yaroslavl Regional Clinical Hospital
Yaroslavl, 150062
Municipal Institution City Clinical Hospital #40
Yekaterinburg, 620102
Romania6 sites
SC Duo Medical SRL
Bucharest, 010584
Spitalul Clinic Sf. Maria
Bucharest, 011172
Spitalul Clinic Colentina
Bucharest, 020125
Centrul de Boli Reumatismale Dr. I. Stoia
Bucharest, 020983
Centrul Medical Terra Med
Cluj-Napoca, Cluj, 400275
Spitalul Clinic Judetean de Urgenta Tg Mures
Târgu Mureş, 540136
Belgium5 sites
AZ Jan Palfijn
Antwerp, 2170
Cliniques Universitaires St Luc Avenue Hippocrate 10 UCL
Brussels, 1200
Universitair Ziekenhuis Gent
Ghent, 9000
Reuma Instituut
Hasselt, 3500
Chu Liege Sart Tilman B 35
Liège, 4000
Colombia4 sites
Centro de Reumatologia y Ortopedia
Barranquilla, Atlántico
Fundacion Instituto de Reumatologia Fernando Chalem
Bogota, Cundinamarca
Medicity S.A.S
Bucaramanga, Santander Department
Servimed EU
Bucaramanga, Santander Department
Hungary4 sites
Budai Irgalmasrendi Hospital
Budapest, 1023
Obudai Egeszsegugyi Centrum Kft
Budapest, 1036
Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft.
Nyíregyháza, 4400
Markusovszky Hospital
Szombathely, 9700
Croatia2 sites
University Hospital Centre Rijeka
Rijeka, 51000
University Hospital Center Zagreb
Zagreb, 10000
Germany1 site
Klinikum Innenstadt der Ludwig-Maximillians-Universität
München, 80336
Mexico1 site
Centro de Estudio de Investigacion Basica y Clinica S.C
Jalisco, Guadalajara, 44690
About this study
Official title: RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.
The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.
- Conditions
- Rheumatoid Arthritis
- Being tested
- Placebo, ILV-094
- Keywords
- Rheumatoid Arthritis, ACR, Methotrexate, Interleukin-22
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboOther
Part 1: Placebo SC administration every 2 weeks X 10 weeks.
ILV-094Drug
Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
ILV-094Drug
Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
PlaceboOther
Part 2: Placebo SC administration every 2 weeks X 10 weeks
ILV-094Drug
Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Placebo comparator | Part 1: Placebo Receives: Other: Placebo |
| Arm 2 | Experimental | Part 1: 100 mg ILV-094 SC Q4W Receives: Drug: ILV-094 |
| Arm 3 | Experimental | Part 1: 100 mg ILV-094 SC Q2W Receives: Drug: ILV-094 |
| Arm 4 | Placebo comparator | Not described Receives: Other: Placebo |
| Arm 5 | Experimental | Part 2: 200 mg ILV-094 SC Q2W Receives: Drug: ILV-094 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12
ACR20 response: greater than or equal to (>=) 20 percent improvement in tender joint count; >=20 percent improvement in swollen joint count; and >=20 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).
Measured: Week 12
Secondary outcomes (15)
Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 2, 4, 6, 8 and 10
ACR20 response: >=20 percent improvement in tender joint count; >=20 percent improvement in swollen joint count; and >=20 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).
Measured: Week 2, 4, 6, 8, 10
Percentage of Participants With an American College of Rheumatology 50 Percent (ACR50) Response at Week 2, 4, 6, 8, 10 and 12
ACR50 response: >=50 percent improvement in tender joint count; >=50 percent improvement in swollen joint count; and 50 improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).
Measured: Week 2, 4, 6, 8, 10, 12
Percentage of Participants With an American College of Rheumatology 70 Percent (ACR70) Response at Week 2, 4, 6, 8, 10 and 12
ACR70 response:>=70 percent improvement in tender joint count; >=70 percent improvement in swollen joint count; and 70 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).
Measured: Week 2, 4, 6, 8, 10, 12
Disease Activity Score Based on 28-Joints Count (DAS28) Using C-Reactive Protein (CRP)
DAS28 (CRP) was calculated from number of swollen joints and tender joints using the 28 joints count; CRP (milligram/Liter [mg/L]); and general health visual analog scale (VAS) score (participant rated scale with scores ranging from 0mm [very well] to 100mm [extremely bad]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 (CRP) less than or equal to (<=) 3.2 implied low disease activity, greater than (>) 3.2 to 5.1 implied moderate to high disease activity, and less than (<) 2.6 implied remission.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
Disease Activity Score Based on 28-Joints Count (DAS28) Using Erythrocyte Sedimentation Rate (ESR)
DAS28 (ESR) was calculated from the number of swollen joints and tender joints using the 28 joints count; ESR (millimeters per hour [mm/hour]); and general health VAS score (participant rated scale with scores ranging from 0 [very well] to 100 [extremely bad]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 (ESR) <=3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity, and <2.6 implied remission.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
Tender Joints Counts (TJC)
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
Swollen Joints Count (SJC)
Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
Physician Global Assessment of Disease Activity
Physician global assessment of disease activity was measured on an 11-point scale, ranging from 0 to 10, where 0 = no disease activity and 10 = extreme disease activity.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
Participant Global Assessment of Disease Activity
Participants answered: "considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a scale ranging from 0 to 10, where 0 = no disease activity and 10 = extreme disease activity.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
Pain Visual Analog Scale (VAS)
Participants assessed the amount of pain currently experienced by them on a 100 millimeter (mm) VAS ranging from 0= no pain to 100= severe pain.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
General Health Visual Analog Scale (VAS)
General health VAS is a 100 mm line marked by the participant. Participants were asked, "In general how would you rate your health currently concerning the arthritis?" Scores ranged from 0 mm = very well to 100 mm = extremely bad.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12
Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Health assessment questionnaire-disability index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to perform activity. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Baseline, Week 4, 2, 6, 8, 10, 12
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey consisting of 36 items summarized into 8 multi-item scales evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality and mental health. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) derived are derived by aggregating the 8 aspects. The score for each aspect and physical and mental component summary are scaled 0-100 where, higher score indicating highest level of functioning.
Measured: Baseline, Week 4, 8, 12
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
FACIT-fatigue is a 13-item questionnaire. Participants score each item on a 5-point scale ranging from 0 (not at all) to 4 (very much). The scoring algorithm is such that the item responses are reversed in score (except for 2 items, "I have energy" and "I am able to do my usual activities"), in order to reflect higher scores as less fatigue. The sum of all responses resulted in the FACIT-fatigue total score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Measured: Baseline, Week 4, 8, 12
Number of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
DAS28-based EULAR response criteria was used to measure individual response as none, good and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline >1.2 with DAS28 =< 3.2; moderate responders: change from baseline >1.2 with DAS28 >3.2 to =<5.1 or change from baseline >0.6 to =<1.2 with DAS28 =<5.1; non-responders: change from baseline =< 0.6 or change from baseline >0.6 and =<1.2 with DAS28 >5.1.
Measured: Week 2, 4, 6, 8, 10, 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2009 (estimated)
- Study start18 Jun 2009
- Primary completion18 Feb 2011
- Study completion18 Feb 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 195 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00883896
- Sponsor's protocol ID
- 3199K1-2001
- Other IDs
- B1981001, 2008-006936-37, 2008
- Status last verified
- Sep 2022
- First submitted
- 17 Apr 2009
- Last updated
- 21 Oct 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.
- ClinicalTrials.gov ID
- NCT00883896
- Acronym / sponsor ID
- 3199K1-2001
- Conditions
- Rheumatoid Arthritis
- Keywords
- Rheumatoid Arthritis, ACR, Methotrexate, Interleukin-22
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 195 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 18 Jun 2009 (actual)
- Primary completion
- 18 Feb 2011 (actual)
- Study completion
- 18 Feb 2011 (actual)
- First posted
- 20 Apr 2009 (estimated)
- Results
- Posted 21 Oct 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Placebo comparator | Other: PlaceboPart 1: Placebo |
| Arm 2 | Experimental | Drug: ILV-094Part 1: 100 mg ILV-094 SC Q4W |
| Arm 3 | Experimental | Drug: ILV-094Part 1: 100 mg ILV-094 SC Q2W |
| Arm 4 | Placebo comparator | Other: Placebo |
| Arm 5 | Experimental | Drug: ILV-094Part 2: 200 mg ILV-094 SC Q2W |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening
- Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following at screening: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h
- Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit.
Key exclusion criteria (3 listed)
- Subjects with other rheumatic diseases
- Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer)
- Any prior use of B cell-depleting therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboPart 1: Placebo SC administration every 2 weeks X 10 weeks. | Other | Arm 1 |
| ILV-094Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks. | Drug | Arm 2 |
| ILV-094Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks. | Drug | Arm 3 |
| PlaceboPart 2: Placebo SC administration every 2 weeks X 10 weeks | Other | Arm 4 |
| ILV-094Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks | Drug | Arm 5 |
Primary outcome
Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12
Time frame: Week 12
ACR20 response: greater than or equal to (>=) 20 percent improvement in tender joint count; >=20 percent improvement in swollen joint count; and >=20 percent improvement in 3 of 5 remaining ACR core measures: participant's global assessment of disease activity (score: 0 [very well] to 10 [worst]); participant's assessment of pain (score: 0 [very well] to 100 [extremely bad]); physician global assessment of disease activity (score: 0 [very well] to 10 [worst]); self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]) (score: 0 [no difficulty] to 3 [unable to do]); and C-reactive protein (CRP).
15 secondary outcomes
Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 2, 4, 6, 8 and 10
Time frame: Week 2, 4, 6, 8, 10
Percentage of Participants With an American College of Rheumatology 50 Percent (ACR50) Response at Week 2, 4, 6, 8, 10 and 12
Time frame: Week 2, 4, 6, 8, 10, 12
Percentage of Participants With an American College of Rheumatology 70 Percent (ACR70) Response at Week 2, 4, 6, 8, 10 and 12
Time frame: Week 2, 4, 6, 8, 10, 12
Disease Activity Score Based on 28-Joints Count (DAS28) Using C-Reactive Protein (CRP)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
Disease Activity Score Based on 28-Joints Count (DAS28) Using Erythrocyte Sedimentation Rate (ESR)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
Tender Joints Counts (TJC)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
Swollen Joints Count (SJC)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
Physician Global Assessment of Disease Activity
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
Participant Global Assessment of Disease Activity
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
Pain Visual Analog Scale (VAS)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
General Health Visual Analog Scale (VAS)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12
Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Time frame: Baseline, Week 4, 2, 6, 8, 10, 12
36-Item Short-Form Health Survey (SF-36)
Time frame: Baseline, Week 4, 8, 12
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
Time frame: Baseline, Week 4, 8, 12
Number of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
Time frame: Week 2, 4, 6, 8, 10, 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
52 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ILV-094 in people with Rheumatoid Arthritis, run by Pfizer at 52 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 52 sites in United States, Japan, Russia, Romania, Belgium and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 21 Oct 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2022.